[1]余红,何庆.欧洲内分泌学会生长激素替代治疗安全性的共识解读——颅咽管瘤术后[J].国际内分泌代谢杂志,2023,43(03):274-277.[doi:10.3760/cma.j.cn121383-20230504-05006]
　Yu Hong,He Qing..Interpretation of the European Endocrine Society Consensus on the safety of growth hormone replacement therapy-Postoperative craniopharyngioma[J].International Journal of Endocrinology and Metabolism,2023,43(03):274-277.[doi:10.3760/cma.j.cn121383-20230504-05006]
点击复制

欧洲内分泌学会生长激素替代治疗安全性的共识解读——颅咽管瘤术后()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年03期
页码:
274-277
栏目:
指南与共识
出版日期:
2023-05-20

文章信息/Info

Title:
Interpretation of the European Endocrine Society Consensus on the safety of growth hormone replacement therapy-Postoperative craniopharyngioma
作者:
余红; 何庆
天津医科大学总医院内分泌代谢科, 天津 300052
Author(s):
Yu Hong;  He Qing.
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
颅咽管瘤;  术后;  生长激素缺乏症;  生长激素替代
Keywords:
Craniopharyngioma;  Postoperative;  Growth hormone deficiency;  Growth hormone replacement
DOI:
10.3760/cma.j.cn121383-20230504-05006
摘要:
2022年,欧洲内分泌学会更新了《在癌症、颅内肿瘤及垂体瘤幸存者中生长激素替代治疗的安全性:共识声明》,共包含了15条国际关注的安全性问题和态度声明。在欧洲内分泌学会的支持下,生长激素研究学会邀请了16个国家涵盖10个专业学会的55位专家组成国际专家小组,讨论了癌症和颅内肿瘤患者生长激素替代安全性的问题,并形成国际专家共识。
Abstract:
In 2022, the European Society of Endocrinology updated Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement, which includes 15 internationally recognized safety issues and attitude statements. With the support of the European Society of Endocrinology, the Growth Hormone Research Society(GRS)convened a workshop, where 55 international key opinion leaders from 16 countries representing 10 professional societies discussed the safety of growth hormone replacement in cancer and intracranial tumor patients and reached an international expert consensus.

参考文献/References:

[1] Boguszewski MCS,Boguszewski CL,Chemaitilly W,et al.Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours:a consensus statement[J].Eur J Endocrinol,2022,186(6):P35-P52.DOI:10.1530/EJE-21-1186.
[2] Müller HL,Merchant TE,Warmuth-Metz M,et al.Craniopharyngioma[J].Nat Rev Dis Primers,2019,5(1):75.DOI:10.1038/s41572-019-0125-9.
[3] Zacharia BE,Bruce SS,Goldstein H,et al.Incidence,treatment and survival of patients with craniopharyngioma in the surveillance,epidemiology and end results program[J].Neuro Oncol,2012,14(8):1070-1078.DOI:10.1093/neuonc/nos142.
[4] Bogusz A,Müller HL.Childhood-onset craniopharyngioma:latest insights into pathology,diagnostics,treatment,and follow-up[J].Expert Rev Neurother,2018,18(10):793-806.DOI:10.1080/14737175.2018.1528874.
[5] Drapeau A,Walz PC,Eide JG,et al.Pediatric craniopharyngioma[J].Childs Nerv Syst,2019,35(11):2133-2145.DOI:10.1007/s00381-019-04300-2.
[6] Jalali R,Maitre M,Gupta T,et al.Dose-constraint model to predict neuroendocrine dysfunction in young patients with brain tumors:data from a prospective study[J].Pract Radiat Oncol,2019,9(4):e362-e371.DOI:10.1016/j.prro.2019.02.011.
[7] Flavelle S,Cummings E.Case 2:An unusual case of delayed puberty[J].Paediatr Child Health,2012,17(9):505-507.DOI:10.1093/pch/17.9.505a.
[8] 中华医学会儿科学分会内分泌遗传代谢学组,中华儿科杂志编辑委员会.过渡期生长激素缺乏症诊断及治疗专家共识[J].中华儿科杂志,2020,58(6):455-460.DOI:10.3760/cma.j.cn112140-20200314-00237.
[9] Yuen KCJ,Biller BMK,Radovick S,et al.American association of clinical endocrinologists and american college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care[J].Endocr Pract,2019,25(11):1191-1232.DOI:10.4158/GL-2019-0405.
[10] Molitch ME,Clemmons DR,Malozowski S,et al.Evaluation and treatment of adult growth hormone deficiency:an Endocrine Society clinical practice guideline[J].J Clin Endocrinol Metab,2011,96(6):1587-1609.DOI:10.1210/jc.2011-0179.
[11] 中华医学会内分泌学分会.成人生长激素缺乏症诊治专家共识(2020版)[J].中华内分泌代谢杂志,2020,36(12):995-1002.DOI:10.3760/cma.j.cn311282-20201130-00798.
[12] 茅江峰,王曦,熊舒煜,等.重组人生长激素替代治疗对颅咽管瘤术后成人患者代谢指标的影响[J].中华医学杂志,2017,97(42):3286-3290.DOI:10.3760/cma.j.issn.0376-2491.2017.42.003.
[13] 中华医学会神经外科学分会小儿神经外科学组,《颅咽管瘤治疗专家共识(2016)》编写委员会.颅咽管瘤治疗专家共识(2016)[J].中华医学杂志,2017,97(17):1283-1289.DOI:10.3760/cma.j.issn.0376-2491.2017.17.002.
[14] Olsson DS,Buchfelder M,Wiendieck K,et al.Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up[J].Eur J Endocrinol,2012,166(6):1061-1068.DOI:10.1530/EJE-12-0077.
[15] Smith TR,Cote DJ,Jane JA Jr,et al.Physiological growth hormone replacement and rate of recurrence of craniopharyngioma:the Genentech National Cooperative Growth Study[J].J Neurosurg Pediatr,2016,18(4):408-412.DOI:10.3171/2016.4.PEDS16112.
[16] Woodmansee WW,Zimmermann AG,Child CJ,et al.Incidence of second neoplasm in childhood cancer survivors treated with GH:an analysis of GeNeSIS and HypoCCS[J].Eur J Endocrinol,2013,168(4):565-573.DOI:10.1530/EJE-12-0967.
[17] Child CJ,Conroy D,Zimmermann AG,et al.Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients:analyses from the Hypopituitary Control and Complications Study[J].Eur J Endocrinol,2015,172(6):779-790.DOI:10.1530/EJE-14-1123.
[18] Alotaibi NM,Noormohamed N,Cote DJ,et al.Physiologic growth hormone-replacement therapy and craniopharyngioma recurrence in pediatric patients:a meta-analysis[J].World Neurosurg,2018,109:487-496.e1.DOI:10.1016/j.wneu.2017.09.164.
[19] Tamhane S,Sfeir JG,Kittah NEN,et al.GH therapy in childhood cancer survivors:a systematic review and meta-analysis[J].J Clin Endocrinol Metab,2018,103(8):2794-2801.DOI:10.1210/jc.2018-01205.
[20] Losa M,Castellino L,Pagnano A,et al.Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence[J].J Clin Endocrinol Metab,2020,105(5):dgaa089.DOI:10.1210/clinem/dgaa089.
[21] Boguszewski MCS,Cardoso-Demartini AA,Boguszewski CL,et al.Safety of growth hormone(GH)treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice[J].Pituitary,2021,24(5):810-827.DOI:10.1007/s11102-021-01173-0.
[22] Raman S,Grimberg A,Waguespack SG,et al.Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the pediatric endocrine society drug and therapeutics committee[J].J Clin Endocrinol Metab,2015,100(6):2192-2203.DOI:10.1210/jc.2015-1002.
[23] Sklar CA,Antal Z,Chemaitilly W,et al.Hypothalamic-pituitary and growth disorders in survivors of childhood cancer:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2018,103(8):2761-2784.DOI:10.1210/jc.2018-01175.
[24] 颅咽管瘤治疗专家共识编写委员会,中华医学会神经外科学分会小儿神经外科学组.颅咽管瘤患者长期内分泌治疗专家共识(2017)[J].中华医学杂志,2018,98(1):11-18.DOI:10.3760/cma.j.issn.0376-2491.2018.01.004.
[25] Nguyen Quoc A,Beccaria K,Briceño LG,et al.Growth hormone and childhood-onset craniopharyngioma:When to initiate growth hormone replacement therapy?[J].J Clin Endocrinol Metab,2023,dgad079.DOI:10.1210/clinem/dgad079.
[26] Grimberg A,Divall SA,Polychronakos C,et al.Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents:growth hormone deficiency,idiopathic short stature,and primary insulin-like growth factor-I deficiency[J].Horm Res Paediatr,2016,86(6):361-397.DOI:10.1159/000452150.
[27] Inzaghi E,Cianfarani S.The challenge of growth hormone deficiency diagnosis and treatment during the transition from puberty into adulthood[J].Front Endocrinol(Lausanne),2013,4:34.DOI:10.3389/fendo.2013.00034.

相似文献/References:

[1]吴蔚,杨叶虹,李益明.下丘脑性肥胖临床研究进展[J].国际内分泌代谢杂志,2014,(01):32.[doi:10.3760/cma.j.issn.1673-4157.2014.01.009]
　Wu Wei,Yang Yehong,Li Yiming.Clinical progress in hypothalamic obesity[J].International Journal of Endocrinology and Metabolism,2014,(03):32.[doi:10.3760/cma.j.issn.1673-4157.2014.01.009]
[2]冯英.颅咽管瘤中肥胖的机制与影响[J].国际内分泌代谢杂志,2017,37(05):352.
　Feng Ying..The mechanism and effect of obesity in craniopharyngioma[J].International Journal of Endocrinology and Metabolism,2017,37(03):352.
[3]申丹丹 贾红蔚 刘铭 何庆 郑方遒.颅咽管瘤术后垂体功能减退患者糖代谢异常危险因素研究[J].国际内分泌代谢杂志,2022,42(04):293.[doi:10.3760/cma.j.cn121383-20210104-01006]
　Shen Dandan,Jia Hongwei,Liu Ming,et al.Study on the risk factors of abnormal glucose metabolism in patients with hypopituitarism after craniopharyngioma surgery[J].International Journal of Endocrinology and Metabolism,2022,42(03):293.[doi:10.3760/cma.j.cn121383-20210104-01006]

备注/Memo

备注/Memo:
通信作者:何庆, Email: hech69@163.com
基金项目:天津市医学重点学科(专科)建设项目(TJYXZDXK-030A); 天津市科技局重大专项(21ZXJBSY00060); 天津市卫生健康委员会科技项目(ZC20210,RC20126)
更新日期/Last Update: 2023-05-20